The Oncolytic Virus Therapy Market is estimated to grow at a 25% CAGR during the forecast period for 2024-2031.
In recent decades, the healthcare burden of Cancer increasing rapidly with an increasing incidence rate. The massive investment in research and development has been implemented to find innovative drugs/therapy/Immuno oncology solutions to cure cancer. Some of them gaining interest include oncolytic viruses therapy, stem cell therapies, adoptive cell therapies, etc. Treatment-related off-target effects, side effects, and drug resistance hamper the efficacies of many therapeutic options. Therefore, scientists are working to develop new, effective therapies with low or no toxicity in normal cells. Oncolytic viruses therapy has shown immense opportunities and potential to be tapped in the future to enhance the cancer treatment. Immunotherapy with oncolytic viruses would definitely build survival solutions with significant importance.
Market Segmentation
The global oncolytic viruses therapy market is segmented on the basis of product, application, and region. Based on the products, the market is divided into Adenoviruses, Herpes Simplex Virus, Vesicular Stomatitis Virus, Vaccinia Virus, and Newcastle Disease Virus. On the basis of application type, the market is segmented into Breast Cancer, Prostate Cancer, Melanoma, Ovarian Cancer, and Others. Based on region, the market is studied across North America, Asia-Pacific, Europe, and LAMEA. Among that, Europe held the largest share of the oncolytic viruses therapy market, followed by America and Asia Pacific. On the other hand, North America is expected to dominate the oncolytic viruses therapy market during the analysis of the forecast period.
Competitive Landscape
Some major key players in the Oncolytic Virus Therapy Market:
- Provectus Biopharmaceuticals, Inc.,
- Takara Bio Inc.,
- SillaJen, Inc.,
- Oncorus, Inc.,
- Amgen,
- OncoMyx Therapeutics, Inc.,
- Replimune Inc.,
- Oncolytics Biotech,
- Vyriad, Inc.,
- Viralytics,
- Transgene SA,
- OncolysBioPharma,
- Unleash ImmunoOncolytics, Inc.,
- TargovaxPsiOxus Therapeutics,
- Sorrento Therapeutics,
- Lokon Pharma AB,
- Genelux Corporation,
- TILT Biotherapeutics,
- Cold Genesys
- Western Oncolytics.
The Oncolytic Virus Therapy Market Report Scope
Report Attribute |
Specifications |
Market Size Value In 2023 |
USD XX Million |
Revenue Forecast In 2031 |
USD XX Million |
Growth Rate CAGR |
CAGR of 25% from 2024 to 2031 |
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
Historic Year |
2019 to 2023 |
Forecast Year |
2024-2031 |
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
Segments Covered |
By Product, By Application |
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
Competitive Landscape |
Provectus Biopharmaceuticals, Inc., Takara Bio Inc., SillaJen, Inc., Oncorus, Inc., Amgen, OncoMyx Therapeutics, Inc., Replimune Inc., Oncolytics Biotech, Vyriad, Inc., Viralytics, Transgene SA, OncolysBioPharma, Unleash ImmunoOncolytics, Inc., TargovaxPsiOxus Therapeutics, Sorrento Therapeutics, Lokon Pharma AB, Genelux Corporation, TILT Biotherapeutics, Cold Genesys and Western Oncolytics. |
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |